Evidence map›Paper›PMID 28094011›Full record

ReviewCell metabolism2017

Metabolomics and Metabolic Diseases: Where Do We Stand?

Christopher B Newgard

Registry-linked trialAbstract readReview
In one paragraph

Review in Cell metabolism, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT04117204 (Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.), which is not on this map. Cited by 428 papers, 3 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
428citing papers in PubMed, 3 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT04117204 nacompletednot on this mapstarted 2019, after this paper: background citation

Identifying a Cardiorenal Protective Diet in a Lower-income African American Population With Chronic Kidney Disease at Risk for Cardiovascular Disease.

TypeinterventionalSponsorBaylor Research InstituteRan2019 to 2020Enrolled101ConditionsChronic Kidney Diseases, Cardiovascular Diseases, HypertensionArmsFruits and Vegetables
3 · Its place in the literature

Who cites it

428 citing papers in PubMed, 3 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Trial
  5. Trial
  6. Trial
  7. Review
  8. Article
  9. Expanding the pig metabolomics QTL catalog.Genetics, selection, evolution : GSE · 2026
    Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Review
  15. Article
  16. Review
  17. Article
  18. Review
  19. Article
  20. Article

368 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

1 author.

Christopher B NewgardSarah W. Stedman Nutrition and Metabolism Center, Duke Molecular Physiology Institute, Departments of Pharmacology & Cancer Biology and Medicine, Duke University Medical Center, Durham, NC 27701, USA. Electronic address: chris.newgard@duke.edu.

Funding

TARGETED RESPONSIVE MR AND PET AGENTS FOR B-CELL IMAGINGP01DK058398 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI MUOIO, DEBORAH M · 2000 to 2016
$26.1M
REVERSIBLE MITOCHONDRIAL PROTEIN ACETYLATION AND METABOLIC REGULATIONR24DK085610 · NIDDK · J. DAVID GLADSTONE INSTITUTES · PI VERDIN, ERIC M. · 2010 to 2019
$16.0M
Trace the flow of genes in the gut microbiome of obese and lean twin pairsP01DK078669 · NIDDK · WASHINGTON UNIVERSITY · PI GORDON, JEFFREY I · 2007 to 2018
$16.0M
ENGINEERED GLUCOSE METABOLISM IN INSULIN-SECRETING CELLSR01DK046492 · NIDDK · UNIVERSITY OF TEXAS SW MED CTR/DALLAS · PI NEWGARD, CHRISTOPHER B · 1993 to 2025
$7.8M
Engineered Glucose Metabolism in Insulin Secreting CellsR37DK046492 · NIDDK · DUKE UNIVERSITY · PI NEWGARD, CHRISTOPHER B · 2003 to 2010
$3.5M
NIDDK NIH HHS P01 DK058398NIDDK NIH HHS P01 DK078669NIDDK NIH HHS R01 DK046492NIDDK NIH HHS R24 DK085610NIDDK NIH HHS R37 DK046492
6 · The paper itself

Abstract

Metabolomics, or the comprehensive profiling of small molecule metabolites in cells, tissues, or whole organisms, has undergone a rapid technological evolution in the past two decades. These advances have led to the application of metabolomics to defining predictive biomarkers for incident cardiometabolic diseases and, increasingly, as a blueprint for understanding those diseases' pathophysiologic mechanisms. Progress in this area and challenges for the future are reviewed here.

Indexed as

MetabolomicsAnimalsDisease Models, AnimalHumansMetabolic DiseasesMetabolomeModels, BiologicalTreatment Outcomecardiovascular diseasesdiabetesmetabolic diseasesmetabolismmetabolomicsobesity

Identifiers

PMID28094011
PMCPMC5245686

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.